Deferoxamine attenuates iron-induced oxidative stress and prevents mitochondrial aggregation and α-synuclein translocation in SK-N-SH cells in culture

被引:76
作者
Sangchot, P
Sharma, S
Chetsawang, B
Porter, J
Govitrapong, P
Ebadi, M
机构
[1] Univ N Dakota, Sch Med & Hlth Sci, Dept Pharmacol Physiol & Therapeut, Grand Forks, ND 58203 USA
[2] Mahidol Univ, Inst Sci & Technol Res & Dev, Neurobehav Biol Ctr, Salaya, Nakornpathom, Thailand
关键词
iron overload; oxidative stress; mitochondria; lipid peroxidation; dopamine; substantial nigra; complex I; alpha-synuclein; Parkinson's disease;
D O I
10.1159/000065700
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
One of the defining characteristics of neurodegenerative diseases, including Parkinson's disease, is an abnormal accumulation of iron in the affected brain areas. By using SK-N-SH, a dopaminergic cell line, we have found that iron (100-250 muM FeSO4) decreased cell viability, increased lipid peroxidation, and the said effects were blocked by deferoxamine (DFO: 10 muM). Furthermore, DFO, in the absence of iron, enhanced the level of adenosine triphosphate (ATP), but caused chromatin condensation and cell death. Morphological studies revealed that iron (50-100 muM) altered mitochondrial morphology, disrupted nuclear membrane, and translocated a-synuclein from perinuclear region into the disrupted nucleus. The results of these studies suggest that DFO is able to block and attenuate iron-mediated oxidative stress. However, in the absence of excess iron, DFO itself may have deleterious effects on the morphology and hence integrity of dopaminergic neurons. Copyright (C) 2002 S. Karger AG, Basel.
引用
收藏
页码:143 / 153
页数:11
相关论文
共 24 条
[11]   Iron metabolism, free radicals, and oxidative injury [J].
Emerit, J ;
Beaumont, C ;
Trivin, F .
BIOMEDICINE & PHARMACOTHERAPY, 2001, 55 (06) :333-339
[12]   NEUROTOXICITY ASSOCIATED WITH DEFEROXAMINE THERAPY [J].
FREEDMAN, MH ;
BOYDEN, M ;
TAYLOR, M ;
SKARF, B .
TOXICOLOGY, 1988, 49 (2-3) :283-290
[13]   OPPOSITE EFFECTS OF 2 METAL-CHELATORS ON ALLOXAN-INDUCED DIABETES IN MICE [J].
GRANKVIST, K ;
MARKLUND, SL .
LIFE SCIENCES, 1983, 33 (25) :2535-2540
[14]   INHIBITION OF THE IRON-CATALYZED FORMATION OF HYDROXYL RADICALS FROM SUPEROXIDE AND OF LIPID PEROXIDATION BY DESFERRIOXAMINE [J].
GUTTERIDGE, JMC ;
RICHMOND, R ;
HALLIWELL, B .
BIOCHEMICAL JOURNAL, 1979, 184 (02) :469-472
[15]   THE EFFECT OF AGE ON THE NON-HAEMIN IRON IN THE HUMAN BRAIN [J].
HALLGREN, B ;
SOURANDER, P .
JOURNAL OF NEUROCHEMISTRY, 1958, 3 (01) :41-51
[16]   The role of iron in neurodegeneration - Prospects for pharmacotherapy of Parkinson's disease [J].
Jellinger, KA .
DRUGS & AGING, 1999, 14 (02) :115-140
[17]  
LEVINE RL, 1990, METHOD ENZYMOL, V186, P464
[18]  
Nelson SK, 1998, ADV MOL CEL, V25, P157
[19]  
REDDY BR, 1985, FREE RADICAL BIO MED, V7, P45
[20]   REDUCTION IN THE RATE OF ETHANOL ELIMINATION INVIVO BY DESFERRIOXAMINE AND DIETHYLENETRIAMINEPENTAACETIC ACID - SUGGESTION FOR INVOLVEMENT OF HYDROXYL RADICALS IN ETHANOL OXIDATION [J].
SINACEUR, J ;
RIBIERE, C ;
ABUMURAD, C ;
NORDMANN, J ;
NORDMANN, R .
BIOCHEMICAL PHARMACOLOGY, 1983, 32 (15) :2371-2373